The R.E.N.A.L. score’s relevance in determining perioperative and oncological outcomes: a Middle-Eastern tertiary care center experience

Nassib Abou Heidar1*, Nizar Hakam2, Jose M El-Asmar3, Jad Najdi4, Mark A. Khauli5, Jad Degheili5, Albert El-Hajji6, Rami Nasr7, Wassim Wazzan8, Muhammad Bulbul8, Deborah Mukherji9 and Raja Khauli4

*Division of Urology and Renal Transplantation, American University of Beirut Medical Center, Beirut, Lebanon; 1The Breyer Lab, University of California San Francisco, San Francisco, California, United States; 2Massachusetts General Hospital, Boston, Massachusetts

ABSTRACT

Objective: The aim of this study is to evaluate the significance of the R.E.N.A.L nephrometry scoring system in predicting perioperative and oncological outcomes and determining the surgical approach of choice for kidney tumors.

Patients and Methods: Our study retrospectively reviewed outcomes from the year 2002 to 2017. Mann-Whitney U test was used to compare continuous variables and chi-square test was used to compare categorical variables. Kaplan-Meier estimates and multivariable cox proportional hazard regression were performed to determine an association between the different R.E.N.A.L categories and disease recurrence or mortality.

Results: A total of 325 patients underwent kidney surgery. The most common R.E.N.A.L score category in our cohort study was intermediate (41.2%), followed by low (33.2%) and high (25.5%). Patients with a high R.E.N.A.L score had worse perioperative outcomes compared to those with a low R.E.N.A.L score. High R.E.N.A.L score patients were 3 times more likely to receive blood transfusions compared to those with a low R.E.N.A.L score (19.4% vs 6.3%, p = 0.018), and a significantly statistically longer hospital stay of was also observed between the two groups (median 4.5 vs 4 days, p = 0.00419). In addition, the only predictor of disease recurrence or mortality was a high R.E.N.A.L score (Hazard Ratio (HR) 3.65, 95% Confidence Interval (CI) 1.05–12.7, p = 0.04).21

Conclusion: Our study sheds light on the use of R.E.N.A.L nephrometry score in predicting perioperative, postoperative, and oncological outcomes. Such findings may play a role in optimizing surgical approaches and pre-operative patient counseling.

Introduction

Partial nephrectomy (PN) is the most widely utilized surgical approach in the management of stage 1 localized kidney tumors [1,2]. PN, whenever feasible, provides similar oncologic outcomes to radical nephrectomy (RN) while at the same time allowing for the preservation of functional renal parenchyma [3]. Widespread use of cross-sectional imaging has increased the overall incidence of renal tumors and has resulted in overall stage migration towards more localized kidney tumors [4]. The increased incidence of incidentally found small kidney tumors, in addition to the introduction of minimally-invasive surgical techniques popularized PN. However, Figure 2 the feasibility of PN is dependent on many patient-related variables as well as on certain tumor characteristics [5].

The decision to perform PN relies heavily on tumor characteristics; however, patients’ comorbidities and overall general health should also be taken into consideration during preoperative assessment. Older age, male gender, medical comorbidities (coronary artery disease, congestive heart failure, diabetes, and hypertension), smoking and obesity have all been shown to be associated with postoperative complications and decreased survivorship after PN [6].

To objectively evaluate tumor complexity, the R.E.N.A.L nephrometry score has been introduced as a standardized tool that relies solely on anatomical variables. These variables include mass radius, percent volume of the mass that is exophytic, proximity to renal sinus, and location [7]. Other nephrometry scores have been devised as well including the C-index, which estimates the mass’ proximity to the renal center [8], and the PADUA score, which utilizes similar characteristics as the R.E.N.A.L scoring system such as tumor size and location [9]. Multiple studies have shown close association between the aforementioned tumor complexity scores and operative difficulty, peri-operative complications, and intraoperative conversion to RN [10,11]. Their use in preoperative assessment has been vital in the decision making towards undergoing partial versus RN.

The aim of this study is to assess the impact of the complexity of renal tumors, stratified by the R.E.N.A.L nephrometry scoring system, on surgical outcomes, postoperative complications, as well as oncological

CONTACT Raja Khauli rkhauli@aub.edu.lb Urology and Surgery, American University of Beirut Medical Center; Urology, University of Massachusetts Medical Center; Director Middle East Prostate Cancer Consortium (MEPCC), P.O.Box 11-0236/ Riad Solh 1107 2020 Beirut, Lebanon © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
outcomes in patients undergoing PN versus RN at a single institution, coinciding with adoption of robotic assistance.

**Methods**

After institutional review board approval, a retrospective chart review was performed for patients with renal cell carcinoma (RCC) who underwent surgical treatment at a tertiary care center. De-identified data was collected for patients treated between 2002 and 2017 to allow a minimum of 3 years of patient follow-up. Data extracted included clinical parameters such as age, sex, medical comorbidities, tumor pathologic characteristics (tumor size, stage, Fuhrman grade, histology, margin status), surgical characteristics (type of surgery (partial vs radical nephrectomy), approach (open vs laparoscopic vs robotic), estimated blood loss, warm ischemia time), pre-operative renal function, and peri-operative complications. R.E.N.A.L nephrometry score was calculated for all patients and categorized into 3 groups: low (≤6), intermediate (7–9), and high (≥10).

Follow-up visits consisted of one post-operative visit at 1–2 weeks and following that, two visits per year for follow up cross sectional imaging. Disease recurrence was defined as any local or distant tumor detection with or without histopathological confirmation.

Descriptive statistics were reported as frequencies and percentages or medians and interquartile ranges (IQR). Univariate analysis was performed to explore associations between R.E.N.A.L categories and patient or tumor characteristics. Mann-Whitney U test was used to compare continuous variables and chi-square test was used to compare categorical variables. The yearly proportion of patients undergoing partial nephrectomy within each R.E.N.A.L category was determined, and trends over time were calculated using linear regression. Multivariable logistic regression was used to explore whether R.E.N.A.L score independently predicted surgery type thus influencing clinical decision making, with a priori adjustment for age, clinical T stage, pre-operative creatinine, medical comorbidities (coronary artery disease, hypertension, and diabetes mellitus). Model fit was assessed using Hosmer-Lemeshow goodness of fit test. Estimates of the probability of disease recurrence or mortality were calculated using Kaplan-Meier estimates. The log rank test was used to compare outcomes of patients with low, intermediate, and high R.E.N.A.L categories. Multivariable Cox proportional hazard regression was performed to test whether R.E.N.A.L categories were associated with disease recurrence or mortality, controlling for age, gender, pathological stage, grade, histology, and type of surgery. Statistical analysis was performed using Stata® version 16.1, and statistical significance was deemed at p < 0.05.

**Results**

We identified 235 patients who underwent kidney surgery with complete data for analysis. The median age was 59 years (IQR 48–66) and 167 (71%) were males. None of the patients had a postoperative urinary leak. The most common R.E.N.A.L score category was intermediate (41.2%), followed by low, (33.2%) and high (25.5%). Table 1 depicts the clinical characteristics of patients, stratified by R.E.N.A.L category. Among patients with clinical stage T1a-2b, R.E.N.A.L category was associated with pathologic upstaging to T3 (1.4% in low vs 11.5% in intermediate and 9.8% in high, p = 0.041). In those upstaged to pT3, median R.E.N.A.L was 9 (IQR 7–10) vs 7 (IQR 6–9) in those without upstaging, p = 0.0408. Table 2 shows the post-operative outcomes and complications stratified by R.E.N.A.L categories. Patients with a high R.E.N.A.L score were 3 times more likely to receive blood transfusion compared to those with low R.E.N.A.L score (19.4% vs 6.3%, p = 0.018), and had a slightly longer hospital length of stay (median 4.5 vs 4 days, p = 0.0419).

The R.E.N.A.L score was also associated with choice of surgical procedure, where PN was performed in 75.6% of cases with low score, vs 54.6% of cases with intermediate score (p = 0.004), and only 11.7% of those with high score (p < 0.001). On multivariate analysis, after adjusting for age, clinical T stage, preoperative creatinine, and comorbidities, increasing R.E.N.A.L score by one category was associated with a stepwise decrease in odds of undergoing PN compared to patients with low R.E.N.A.L score (intermediate: OR = 0.41, CI 0.17–0.97, p = 0.042; high: OR = 0.05, CI 0.02–0.18, p < 0.001). However, Figure 1 demonstrates a significant trend over time of increased use of PN for patients with low category (p = 0.015, R² = 0.402) and intermediate category (p = 0.016, R² = 0.373), but not for high category (p = 0.294, R² = 0.08).

Over a median follow-up of 4.4 years (IQR 2.3–6.9), 48 patients (20.4%) experienced disease recurrence or mortality. The overall 3, 5, and 10-year freedom of disease recurrence or mortality were 92% (CI 87% – 95%), 81% (CI 75% – 86%), and 62% (CI 51% – 72%). When stratified by R.E.N.A.L category, freedom from disease recurrence or mortality did not differ significantly (log-rank p = 0.1176). On multivariate analysis (Table 3), the only predictor of disease recurrence or mortality was high R.E.N.A.L score (HR 3.65, CI 1.05–12.7, p = 0.041), while an intermediate R.E.N.A.L score showed a statistically insignificant increased risk (HR = 2.34, CI 0.81–6.81, p = 0.117).

**Discussion**

In managing renal masses, the choice of procedure (PN or RN) and approach (open or minimally invasive) classically depends on qualitative data such as
tumor anatomy, patient characteristics, and surgical expertise. Nephrometry scoring systems played a major role in quantifying and stratifying the complexity of renal masses. The R.E.N.A.L nephrometry score utilizes imaging related factors of renal masses to objectively assess tumor complexity aiding in the decision-making process of the elected procedure and type of approach used [7]. In patients undergoing open or minimally-invasive PN, the R.E.N.A.L score has been shown to be associated with perioperative outcomes [12,13]. Our study validates the utility of the R.E.N.A.L nephrometry score in predicting operative complexity and postoperative morbidity.

In keeping with available literature, our series shows that most patients with high R.E.N.A.L score tumors underwent RN as most of these tumors are anatomically complex and thus not amenable to PN [14]. Our data additionally reveals that when dealing with low and intermediate R.E.N.A.L score tumors there was an increased trend with time favoring PN especially since our institutions’ adoption of robotic surgery in the early 2010s. Similarly, Ali et al. report on a major increase in the use of PN for treating renal masses, up to 60% in 2016 from a previous 5% rate in 2010. Authors conclude that the increased use of the robotic surgery platform is the main culpable for the change in numbers [15]. It is quite evident that the introduction

### Table 1. Clinical Characteristics of patients treated with surgery for RCC.

| Low (≤6) | Intermediate (7–9) | High (≥10) | p | p |
|----------|--------------------|------------|---|---|
| N 78     | 97                 | 60         |   |   |
| Median Age (IQR) 58 (49–64) | 60 (50–67) | 59 (47–69) | 0.2778 | 0.3879 |
| Gender | 0.563              | 0.258      |   |   |
| Male 53 (67.1) | 69 (71.1) | 47 (75.8) | 0.0019 | < 0.0001 |
| Tumor size 3.2 (2.5–5) | 4.5 (3.4–7) | 8 (6–11) | < 0.0001 | < 0.0001 |
| Pathologic T stage | 0.002 | 0.032 |
| T1a 52 (67.5) | 38 (41.3) | 8 (13.8) |   |   |
| T1b 13 (16.9) | 31 (33.7) | 16 (27.6) |   |   |
| T2a 5 (6.49) | 7 (7.61) | 9 (15.5) |   |   |
| T2b 3 (3.9) | 1 (1.09) | 5 (8.62) |   |   |
| T3a 2 (2.6) | 12 (13.0) | 12 (20.7) |   |   |
| T3b 0 | 0 | 3 (5.17) |   |   |
| T3c 0 | 0 | 1 (1.72) |   |   |
| T4 2 (2.6) | 3 (3.26) | 4 (6.9) |   |   |
| Fuhrman Grade | 0.461 | 0.783 |
| 1–2 43 (55.1) | 51 (52.6) | 26 (43.3) |   |   |
| 3–4 19 (24.4) | 31 (31.9) | 27 (45) |   |   |
| Unknown 16 (20.5) | 15 (15.3) | 7 (11.7) |   |   |
| Histology | 0.618 | 0.783 |
| Clear cell 49 (63.6) | 57 (58.8) | 38 (61.3) |   |   |
| Papillary 9 (11.7) | 11 (11.34) | 7 (11.3) |   |   |
| Chromophobe 11 (14.3) | 21 (21.7) | 10 (16.1) |   |   |
| Other 8 (10.4) | 8 (8.2) | 7 (11.3) |   |   |
| Sarcomatoid 3 (3.8) | 2 (2.06) | 4 (6.45) | 0.699 |   |
| LVI 2 (2.53) | 5 (5.15) | 11 (17.7) | < 0.0001 | < 0.0001 |
| Surgery type | 0.04 | 0.002 |
| PN 59 (75.6) | 53 (54.6) | 7 (11.7) |   |   |
| RN 19 (24.4) | 44 (45.4) | 53 (88.3) |   |   |
| Median EBL (IQR) 200 (100–300) | 200 (150–400) | 0.1443 | 200 (100–300) | 0.109 |
| Transfusion 5 (6.33) | 15 (15.5) | 0.058 | 12 (19.4) | 0.018 |
| Positive margin 4 (5.06) | 5 (5.15) | 1 (1.61) | 0.385 |   |
| Ischemia Time 20 (15 – 25) | 20.5 (12–27) | 0.92 | 22 (17–25) | 0.7929 |

IQR: Inter-Quartile Range
EBL: Estimated Blood loss
RN: Robotic Nephrectomy
PN: Partial Nephrectomy

### Table 2. Peri-operative and post-operative outcomes stratified according to R.E.N.A.L category.

| Low (≤6) | Intermediate (7–9) | High (≥10) | p | p |
|----------|--------------------|------------|---|---|
| Median Ischemia time (IQR) 20 (15–25) | 20.5 (12–27) | 22 (17–25) | 0.7929 |   |
| Median EBL (IQR) 200 (100–300) | 200 (150–400) | 200 (100–300) | 0.109 |   |
| Transfusion 5 (6.33) | 15 (15.5) | 12 (19.4) | 0.018 |   |
| LOS 4 (3–5) | 4 (3–5) | 4.5 (3–5) | 0.0419 |   |
| Any complication 10 (12.66) | 13 (13.4) | 10 (16.1) | 0.558 |   |
| Readmission 4 (5.06) | 3 (3.09) | 0 (0) | 0.131 |   |
of minimally invasive surgery, namely robotic surgery, created a worldwide trend favoring nephron-sparing surgery which led to improved peri-operative outcomes even for highly complex tumors when compared to the traditional open partial nephrectomy technique [16].

In our series, patients with a higher R.E.N.A.L score tumors were more likely to receive blood transfusions and have an extended length of hospital stay. Similarly, a systematic review and metaanalysis of 20 studies showed a clear increase in the incidence of postoperative complications including hemorrhagic ones and urine leaks for patients with higher R.E.N.A.L score tumors [17]. In addition, a higher R.E.N.A.L score was associated with a longer operative time which was in turn directly related to an extended length of hospital stay [18].

The impact of an RCC’s tumor complexity on oncologic outcomes is yet to be established. This study has shown that R.E.N.A.L score has a prognostic effect on significant oncologic outcomes. For instance, patients with low R.E.N.A.L score have a significantly improved survival rate when compared to patients with higher nephrometry scores. Similarly, a higher rate of recurrence and upstaging was revealed with high R.E.N.A.L score tumors. Previously, Kopp et al. showed that high complexity tumors (R.E.N.A.L ≥ 10) had a negative impact on progression-free survival [19]. Whereas, Weight et al. revealed that an increasing R.E.N.A.L score is associated with increased risk of mortality from RCC in addition to all-cause mortality [20]. Interestingly however, in another study by Hwanik et al., tumor radius was the sole factor associated with increased mortality [21].

Our study is not without limitations. To start, our sample consisted of a pool of patients before and after the adoption of robotic assisted surgery at our institution. Complications during the early adoption phase might be in fact related to surgeon expertise which could not be accounted for in our analysis. Moreover, we included a cohort of patients over a long period of time during which indications for PN changed dramatically as this technique was being refined and mastered. Moreover, radiologic data in nephrometry scoring was calculated manually by the authors, which is subject to human error. More importantly,
the relatively small sample size of this study might not allow consequential and generalizable conclusions. Another limitation is that our cox regression model was likely underpowered to assess disease recurrence and mortality separately due to limited outcome events.

**Conclusion**

Our study reiterates the role of the R.E.N.A.L nephrometry score in predicting intra and postoperative complications highlighting its importance in pre-operative surgical planning. Additionally, our results shed light on the significance of a higher R.E.N.A.L score in predicting oncologic outcomes including recurrence and mortality. Future prospective studies investigating the correlation between R.E.N.A.L nephrometry score and oncologic outcomes are needed to further validate its prognostic role in RCC.

**Disclosure statement**

No potential conflict of interest was reported by the author(s).

**ORCID**

Nassib Abou Heidar  http://orcid.org/0000-0003-3811-5543

**References**

[1] Campbell SC, Novick AC, Beldegrun A, et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009 Oct;182(4):1271–1279.

[2] Ljungberg B, Albiger L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: the 2019 Update. Eur Urol. 2019 May;75(5):799–810.

[3] Patard JJ, Shivarts O, Lam JS, et al. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol. 2004 Jun;171(6 Pt 1):2181–2185. quiz 2435.

[4] King SC, Pollack LA, Li J, et al. Continued increase in incidence of renal cell carcinoma, especially in young patients and high grade disease: united States 2001 to 2010. J Urol. 2014 Jun;191(6):1665–1670.

[5] Patel MN, Krane LS, Bhandari A, et al. Robotic Partial Nephrectomy for Renal Tumors Larger Than 4 cm. Eur Urol. 2010;57(2):310–316.

[6] Huynh MJ, Wang Y, Joshi M, et al. Patient factors predict complications after partial nephrectomy: validation and calibration of the Preoperative Risk Evaluation for Partial Nephrectomy (PREP) score. BJU Int. 2021 Mar;127(3):369–374.

[7] Kutikov A, Smaldone MC, Egleston BL, et al. Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the R.E.N.A.L Nephrometry score. Eur Urol. 2011 Aug;60(2):241–248.

[8] Simmons MN, Ching CB, Sampalesski MK, et al. Kidney tumor location measurement using the C index method. J Urol. 2010 May;183(5):1708–1713.

[9] Ficarra V, Novara G, Secco S, et al. Preoperative aspects and dimensions used for an anatomical (Padua) classification of renal tumours in patients who are candidates for nephron-sparing surgery. Eur Urol. 2009 Nov;56(5):786–793.

[10] Okhunov Z, Rais-Bahrami S, George AK, et al. The comparison of three renal tumor scoring systems: c-Index, P.A.D.U.A., and R.E.N.A.L. nephrometry scores. J Endourol. 2011 Dec;25(12):1921–1924.

[11] Basu S, Khan IA, Das RK, et al. RENAL nephrometry score: predicting perioperative outcomes following open partial nephrectomy. Urol Ann. 2019 Apr-Jun;11(2):187–192.
Park DS, Hwang JH, Kang MH, et al. Association between R.E.N.A.L. nephrometry score and perioperative outcomes following open partial nephrectomy under cold ischemia. Can Urol Assoc J. 2014 Mar-Apr;8(3–4):E137–41.

Corradi RB, Vertosick EA, Nguyen DP, et al. Nephrometry scores and perioperative outcomes following robotic partial nephrectomy. Int Braz J Urol. 2017 Nov-Dec;43(6):1075–1083.

Veccia A, Dell’oglio P, Antonelli A, et al. Robotic partial nephrectomy versus radical nephrectomy in elderly patients with large renal masses. Minerva Urol Nefrol. 2020 Feb;72(1):99–108.

Ali S, Ahn T, Papa N, et al. Changing trends in surgical management of renal tumours from 2000 to 2016: a nationwide study of Medicare claims data. ANZ J Surg. 2020 Jan;90(1–2):48–52.

Garisto J, Bertolo R, Dagenais J, et al., editors. Robotic versus open partial nephrectomy for highly complex renal masses: comparison of perioperative, functional, and oncological outcomes. Urologic Oncology: seminars and Original Investigations. Elsevier; 2018, (10):471.e1–471.e9. doi: 10.1016/j.urolonc.2018.06.012.

Shi N, Zu F, Shan Y, et al. The value of renal score in both determining surgical strategies and predicting complications for renal cell carcinoma: a systematic review and meta-analysis. Cancer Med. 2020 Jun;9(11):3944–3953.

Bazzi WM, Sjoberg DD, Grasso AA, et al. Predicting length of stay after robotic partial nephrectomy. Int Urol Nephrol. 2015 Aug;47(8):1321–1325.

Kopp RP, Mehrazin R, Palazzi KL, et al. Survival outcomes after radical and partial nephrectomy for clinical T2 renal tumours categorised by R.E.N.A.L. nephrometry score. BJU Int. 2014 Nov;114(5):708–718.

Weight CJ, Atwell TD, Fazzio RT, et al. A multidisciplinary evaluation of inter-reviewer agreement of the nephrometry score and the prediction of long-term outcomes. J Urol. 2011 Oct;186(4):1223–1228.

Kim H, Kim JK, Ye C, et al. Recurrence after radical and partial nephrectomy in high complex renal tumor using propensity score matched analysis. Sci Rep. 2021 Feb 3;11(1):2919.